Nociceptive Modulation by Inactivation of TRPA1 and TRPV1 Channels Nociceptive modulation of TRPA1/TRPV1
Main Article Content
http://orcid.org/0000-0003-3581-2845
Ivliane Nozadze
Gulnaz Gurtskaia
Maia Tsagareli
Mirela Iodi Cartstens
Gulnara Gedevanishvili
Earl Carstens
Abstract
Background: Pain and itch are unpleasant sensations specifying actual or potential tissue damage. Pain is a necessary alert signal that sets off protective responses, while itch mainly provokes the desire to scratch. Painful or itching stimulation applied to the peripheral receptors evokes a cascade of nociceptive signaling in ascending somatosensory pathways. Transient receptor potential (TRPA1 and TRPV1) channels are involved in pain and itch sensations, making them attractive targets for therapeutics.
Aims: We aimed to investigate pungent nociceptive substances, cinnamon aldehyde (CA), allyl isothiocyanate (AITC, the main compound of mustard oil), and capsaicin (CAPS) from chili peppers, which elicit thermal hyperalgesia and mechanical allodynia in mice, and studied the potential roles of TRP channels in pain modulation.
Methods: We measured nociceptive thermal paw withdrawal latencies (Hargreaves test) and mechanical thresholds (electronic von Frey test) bilaterally in mice at various time points following intraplantar applications of AITC, CA, and CAPS, which produced thermal hyperalgesia and mechanical allodynia.
Results: When pretreated with the TRPA1 antagonist (HC-030031), we found a significant reduction of these pain behavior responses to AITC and CA applications. Pretreatment with the TRPV1 antagonist (capsazepine) produced significant attenuation of thermal hyperalgesia and mechanical allodynia evoked by two doses of CAPS. We thus showed that noxious chemical irritants eliciting thermal hyperalgesia and mechanical allodynia are mediated via the activation of TRPA1 and TRPV1 cation channels.
Conclusion: The discovery of TRP channel antagonists, particularly dual antagonists that simultaneously target both TRPA1/TRPV1 channels, represents a new and promising therapeutic approach for pain treatment.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Tsagareli MG and Carstens EE. Chapter one - allodynia and hyperalgesia in pruritus: involvement of TRP channels. In: Tsagareli MG, and Follansbee T (eds). Histaminergic and Non-Histaminergic Itch. Nova Science: New York, pp. 1–23 (2023)
3. Yuan T, Li J, Shen Le, et al. Chapter one - assessment of itch and pain in animal models and human subjects. In: Ma C, and Huang Y. (eds.) Translational Research in Pain and Itch. 2nd ed., Springer, pp. 1-22 (2024), doi: 10.1007/ 978-981-99-8921-8_1.
4. Motzkin JC, Basbaum AI, Crowther AJ Neuroanatomy of the nociceptive system: From nociceptors to brain networks. Int Rev Neurobiol 2024; 179: 1-39, doi: 10.1016/bs.irn.2024.10.008.
5. McKemy DD. Chapter one - what makes TRP channels attractive therapeutic targets? In: Szallasi A. (ed). TRP Channels as Therapeutic Targets. 2nd ed., Elsevier, pp. 1-7, (2024) doi: 10.1016/B978-0-443-18653-0.00018-6.
6. Rangel-Yescas GE and Islas LD. Chapter two - biology of TRP channels. In: Szallasi A. (ed). TRP Channels as Therapeutic Targets. 2nd ed., Elsevier, pp. 9-34, (2024) doi: 10.1016/B978-0-443-18653-0.00020-4
7. Tsagareli M.G., Nozadze I. An overview on transient receptor potential channels superfamily. Behavioural Pharmacol 2020; 31(5): 413-434, doi: 10.1097/FBP.0000000000000524.
8. Kiselyov K. Chapter five - TRP channelopathies: TRP channel dysfunction in hereditary diseases. In: Szallasi A. (ed). TRP Channels as Therapeutic Targets. 2nd ed., Elsevier, pp. 71-34, (2024) doi: 10.1016/B978-0-443-18653-0.00017-4
9. Düll MM, Riegel K, Tappenbeck J, et al. Methylglyoxal causes pain and hyperalgesia in human through C-fiber activation. Pain 2019; 160(11): 2497-2507, doi: 10.1097/j.pain.0000000000001644.
10. Becker AK, Babes A, Düll MM, et al. Spontaneous activity of specific C-nociceptor subtypes from diabetic patients and mice: Involvement of reactive dicarbonyl compounds and (sensitized) TRPA1 channel. J Peripher Nerv Syst 2023; 28(2): 202-225, doi: 10.1111/jns.12546.
11. Koivisto A, Jalava N, Rantanen M, et al. Chapter twelve - TRPA1 antagonists for pain relief. In: Szallasi A. (ed). TRP Channels as Therapeutic Targets. 2nd ed. Elsevier, pp. 185-202 (2024) doi: 10.1016/B978-0-443-18653-0.00032-0.
12. Talavera K, Startek JB, Alvarez-Collazo J, et al. Mammalian transient receptor potential TRPA1 channels: From structure to disease. Physiol Rev 2020; 100(2): 725-803, doi: 10.1152/physrev.00005.2019.
13. Ann J, Blumberg PM and Lee J. Chapter eleven - TRPV1 antagonists: Future drug discovery directions. In: Szallasi A. (ed). TRP Channels as Therapeutic Targets. 2nd ed., Elsevier, pp. 163-183 (2024), doi: 10.1016/ B978-0-443-18653-0.00022-8.
14. Fernández-Carvajal A, Fernández-Ballester G and Ferrer-Montiel A. TRPV1 in chronic pruritus and pain: Soft modulation as a therapeutic strategy. Front Mol Neurosci 2022; 15: 930964, doi: 10.3389/fnmol.2022.930964.
15. Tsagareli MG, Nozadze I, Tsiklauri N, et al. Thermal hyperalgesia and mechanical allodynia elicited by histamine and non-histaminergic itch mediators: Respective involvement of TRPV1 and TRPA1. Neuroscience 2020; 449: 35-45, doi: 10. 1016/j.neuroscience.2020.09.048.
16. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16(2): 109-110, doi: 10.1016/0 304-3959(83)90201-4.
17. De Logu F, Li Puma S, Landini L, et al. The acyl-glucuronide metabolite of ibuprofen has analgesic and anti-inflammatory effects via the TRPA1 channel. Pharmacol Res 2019; 142: 127-139, doi: 10.1016/ j.phrs.2019.02.019.
18. Nozadze I, Tsiklauri N, Gurtskaia G et al. Role of thermo TRPA1 and TRPV1 channels in heat, cold, and mechanical nociception of rats. Behav Pharmacol 2016; 27(1): 29-36, doi: 10.1097/FBP. 0000000000000176.
19. Nozadze I, Gurtskaia G and Tsagareli MG. TRPV1 and TRPA1 channels are involved in pain sensations. Bull Georgian Natl Acad Sci, New series, 2021; 15(4): 131-139.
20. Tsagareli MG, Nozadze I, Tsiklauri N et al. TRPA1 channel is involved in SLIGRL-evoked thermal and mechanical hyperalgesia in mice. Med Sci 2019; 7(4): 62, doi: 10.3390/medsci7040062.
21. Klein AH, Sawyer CM, Iodi Carstens M, et al. Topical application of L-menthol induces heat analgesia, mechanical allodynia, and a biphasic effect on cold sensitivity in rats. Behav Brain Res 2010; 212(2): 179-186. doi: 10.1016/j.bbr. 2010.04.015.
22. Anand S and Rajagopal S. A comprehensive review on the regulatory action of TRP channels: A potential therapeutic target for nociceptive pain. Neurosci Insights 2023; 18: 26331055231220340, doi: 10.1177/ 26331055231220340
23. Mellado Lagarde MM, Wilbraham D, Martins RF, et al. Clinical proof-of-concept results with a novel TRPA1 antagonist (LY3526318) in 3 chronic pain states. Pain 2024; 166(7): 1497-1518, doi: 10.1097/j.pain. 0000000000003487
24. Koivisto AP, Belvisi MG, Gaudet R, et al. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat Rev Drug Discov 2022; 21(1): 41-59, doi: 10.1038/s41573-021-00268-4.
25. Iftinca M, Defaye M, Altier C. TRPV1-targeted drugs in development for human pain conditions. Drugs 2021; 81(1): 7-27, doi: 10.1007/s40265-020-01429-2.
26. Segerdahl M, Rother M, Halldin MM, et al. Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double-blind, placebo-controlled, crossover study. Eur J Pain 2024; 28(10): 1656-1673, doi: 10.1002/ejp.2299.
27. Wilzopolski J, Kietzmann M, Mishra SK, et al. TRPV1 and TRPA1 channels are both involved downstream of histamine‐induced Itch. Biomolecules 2021; 11(8): 1166, doi: 10.3390/biom11081166.
28. Do N, Zuo D, Kim M, et al. Discovery of dual TRPA1 and TRPV1 antagonists as novel therapeutic agents for pain. Pharmaceuticals 2024, 17: 1209, doi: 10.3390/ ph17091209.